Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults
VAX-31, a 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate, is the Broadest-Spectrum PCV to Enter the Clinic -- -- Topline Safety, Tolerability and…
Valent Pneumococcal Conjugate Vaccine Immunogenicity Data Expected Second Half Provide Coverage Invasive Pneumococcal Disease Circulating Reaking News
Source: biztoc.com